What does a mouse tell us about neuregulin 1 - cannabis interactions?

Frontiers in Cellular Neuroscience

Volumn , Issue FEB, 2013, Pages

  Karl, Tim ^a,b,c   Arnold, Jonathon C ^b,d  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b Schizophrenia Research Institute   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cannabis; Gene environment interactions; Mouse model; Neuregulin 1; Schizophrenia

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; DRONABINOL; NEU DIFFERENTIATION FACTOR;

CANNABIS ADDICTION; CHEMICAL INTERACTION; CHRONIC DISEASE; DISEASE ASSOCIATION; DISEASE MODEL; DNA POLYMORPHISM; DRUG EXPOSURE; DRUG MISUSE; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENE TARGETING; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MUTANT; NEUREGULIN 1 GENE; NEUROBIOLOGY; NEUROPSYCHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; POPULATION GENETICS; PREVENTIVE MEDICINE; PSYCHIATRY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA;

EID: 84873666635     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2013.00018     Document Type: Review

References (45)

1. Abe, Y., Namba, H., Zheng, Y., and Nawa, H. (2009). In situ hybridization reveals developmental regulation of ErbB1-4 mRNA expression in mouse midbrain: implication of ErbB receptors for dopaminergic neurons. Neuroscience 161, 95-110.
2. Allen, N.C., Bagade, S., Mcqueen, M.B., Ioannidis, J.P., Kavvoura, F.K., Khoury, M.J., Tanzi, R.E., and Bertram, L. (2008). Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 40, 827-834.
3. Arnold, J.C., Boucher, A.A., and Karl, T. (2012). The Yin and Yang of Cannabis-induced Psychosis: the Actions of Delta 9-Tetrahydrocannabinol and Cannabidiol in Rodent Models of Schizophrenia. Curr Pharm Des 18, 5113-5130.
4. Bayer, T.A., Falkai, P., and Maier, W. (1999). Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis". J Psychiatr Res 33, 543-548.
5. Behan, A.T., Hryniewiecka, M., O'tuathaigh, C.M., Kinsella, A., Cannon, M., Karayiorgou, M., Gogos, J.A., Waddington, J.L., and Cotter, D.R. (2012). Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology 37, 1773-1783.
6. Boucher, A.A., Arnold, J.C., Duffy, L., Schofield, P.R., Micheau, J., and Karl, T. (2007a). Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 192, 325-336.
7. Boucher, A.A., Hunt, G.E., Karl, T., Micheau, J., Mcgregor, I.S., and Arnold, J.C. (2007b). Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 149, 861-870.
8. Boucher, A.A., Hunt, G.E., Micheau, J., Huang, X., Mcgregor, I.S., Karl, T., and Arnold, J.C. (2011). The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int J Neuropsychopharmacol 14, 631-643.
9. Caspi, A., and Moffitt, T.E. (2006). Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 7, 583-590.
10. Caspi, A., Moffitt, T.E., Cannon, M., Mcclay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., Poulton, R., and Craig, I.W. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57, 1117-1127.
11. Chesworth, R., Downey, L., Logge, W., Killcross, S., and Karl, T. (2012a). Cognition in female transmembrane domain neuregulin 1 mutant mice. Behav Brain Res 226, 218-223.
12. Chesworth, R., Yulyaningsih, E., Cappas, E., Arnold, J., Sainsbury, A., and Karl, T. (2012b). The response of neuregulin 1 mutant mice to acute restraint stress. Neurosci Lett 515, 82-86.
13. Desbonnet, L., Waddington, J.L., and O'tuathaigh, C.M. (2009). Mutant models for genes associated with schizophrenia. Biochem Soc Trans 37, 308-312.
14. Duffy, L., Cappas, E., Lai, D., Boucher, A.A., and Karl, T. (2010). Cognition in transmembrane domain neuregulin 1 mutant mice. Neuroscience 170, 800-807.
15. Duffy, L., Cappas, E., Scimone, A., Schofield, P.R., and Karl, T. (2008). Behavioral profile of a heterozygous mutant mouse model for EGF-like domain neuregulin 1. Behav Neurosci 122, 748-759.
16. Geyer, M.A., Krebs-Thomson, K., Braff, D.L., and Swerdlow, N.R. (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156, 117-154.
17. Han, S., Yang, B.Z., Kranzler, H.R., Oslin, D., Anton, R., Farrer, L.A., and Gelernter, J. (2012). Linkage Analysis Followed by Association Show NRG1 Associated with Cannabis Dependence in African Americans. Biol Psychiatry.
18. Harrison, P.J., and Law, A.J. (2006). Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology. Biol Psychiatry 60, 132-140.
19. Henquet, C., Murray, R., Linszen, D., and Van Os, J. (2005). The environment and schizophrenia: the role of cannabis use. Schizophr Bull 31, 608-612.
20. Henquet, C., Rosa, A., Krabbendam, L., Papiol, S., Fananas, L., Drukker, M., Ramaekers, J.G., and Van Os, J. (2006). An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31, 2748-2757.
21. Karl, T., Burne, T.H., Van Den Buuse, M., and Chesworth, R. (2011). Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit? Behav Brain Res 223, 336-341.
22. Karl, T., Duffy, L., Scimone, A., Harvey, R.P., and Schofield, P.R. (2007). Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav 6, 677-687.
23. Kofalvi, A. (2008). Cannbinoids and the brain. New York: Springer.
24. Lacroix-Fralish, M.L., Tawfik, V.L., Nutile-Mcmenemy, N., Harris, B.T., and Deleo, J.A. (2006). Differential regulation of neuregulin 1 expression by progesterone in astrocytes and neurons. Neuron Glia Biol 2, 2227-2234.
25. Law, A.J., Shannon Weickert, C., Hyde, T.M., Kleinman, J.E., and Harrison, P.J. (2004). Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience 127, 125-136.
26. Long, L.E., Chesworth, R., Arnold, J.C., and Karl, T. (2010a). A follow-up study: acute behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psychopharmacology (Berl) 211, 277-289.
27. Long, L.E., Chesworth, R., Huang, X.F., Mcgregor, I.S., Arnold, J.C., and Karl, T. (2010b). A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 13, 861-876.
28. Long, L.E., Chesworth, R., Huang, X.F., Mcgregor, I.S., Arnold, J.C., and Karl, T. (2012a). Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. Int J Neuropsychopharmacol, 1-13.
29. Long, L.E., Chesworth, R., Huang, X.F., Wong, A., Spiro, A., Mcgregor, I.S., Arnold, J.C., and Karl, T. (2012b). Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLoS One 7, e34129.
30. Mcgregor, I.S., and Arnold, J.C. (2007). Cannabis reward: biased towards the fairer sex? Br J Pharmacol 152, 562-564.
31. Mei, L., and Xiong, W.C. (2008). Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 9, 437-452.
32. Munafo, M.R., Thiselton, D.L., Clark, T.G., and Flint, J. (2006). Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry 11, 539-546.
33. Neddens, J., and Buonanno, A. (2011). Expression of the neuregulin receptor ErbB4 in the brain of the rhesus monkey (Macaca mulatta). PLoS One 6, e27337.
34. O'tuathaigh, C.M., Hryniewiecka, M., Behan, A., Tighe, O., Coughlan, C., Desbonnet, L., Cannon, M., Karayiorgou, M., Gogos, J.A., Cotter, D.R., and Waddington, J.L. (2010). Chronic adolescent exposure to Delta-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology 35, 2262-2273.
35. Powell, C.M., and Miyakawa, T. (2006). Schizophrenia-relevant behavioural testing in rode322 nt models: a uniquely human disorder? Biol Psychiatry 59, 1198-1207.
36. Rapoport, J.L., Addington, A.M., Frangou, S., and Psych, M.R. (2005). The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10, 434-449.
37. Sanders, A.R., Duan, J., Levinson, D.F., Shi, J., He, D., Hou, C., Burrell, G.J., Rice, J.P., Nertney, D.A., Olincy, A., Rozic, P., Vinogradov, S., Buccola, N.G., Mowry, B.J., Freedman, R., Amin, F., Black, D.W., Silverman, J.M., Byerley, W.F., Crowe, R.R., Cloninger, C.R., Martinez, M., and Gejman, P.V. (2008). No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry 165, 497-506.
38. Sheehan, T.P., Chambers, R.A., and Russell, D.S. (2004). Regulation of affect by the lateral septum: implications for neuropsychiatry. Brain Res Brain Res Rev 46, 71-117.
39. Stadelmann, A.M., Roser, P., Arning, L., Gallinat, J., Epplen, J.T., and Juckel, G. (2010). Acute effects of delta9-tetrahydrocannabinol on the auditory evoked mismatch negativity are modulated by the NRG1 gene. Pharmacopsychiatry 43, 194-195.
40. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., Chou, T.T., Hjaltason, O., Birgisdottir, B., Jonsson, H., Gudnadottir, V.G., Gudmundsdottir, E., Bjornsson, A., Ingvarsson, B., Ingason, A., Sigfusson, S., Hardardottir, H., Harvey, R.P., Lai, D., Zhou, M., Brunner, D., Mutel, V., Gonzalo, A., Lemke, G., Sainz, J., Johannesson, G., Andresson, T., Gudbjartsson, D., Manolescu, A., Frigge, M.L., Gurney, M.E., Kong, A., Gulcher, J.R., Petursson, H., and Stefansson, K. (2002). Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71, 877-892.
41. Sumner, B.E., Cruise, L.A., Slattery, D.A., Hill, D.R., Shahid, M., and Henry, B. (2004). Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology (Berl) 171, 306-321.
42. Taylor, S.B., Markham, J.A., Taylor, A.R., Kanaskie, B.Z., and Koenig, J.I. (2011). Sex350 specific neuroendocrine and behavioral phenotypes in hypomorphic Type II Neuregulin 1 rats. Behav Brain Res 224, 223-232.
43. Tosato, S., Dazzan, P., and Collier, D. (2005). Association between the neuregulin 1 gene and schizophrenia: a systematic review. Schizophr Bull 31, 613-617.
44. Van Den Buuse, M., Wischhof, L., Lee, R.X., Martin, S., and Karl, T. (2009). Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int J Neuropsychopharmacol 12, 1383-1393.
45. Van Os, J., Kenis, G., and Rutten, B.P. (2010). The environment and schizophrenia. Nature 468, 203-212.